CN-121971558-A - A composition containing germinated herba Avenae Fatuae extract for preventing or treating inflammatory bowel disease

Abstract

The present invention relates to a composition for preventing, improving or treating inflammatory bowel disease comprising germinated oat extract, which is useful in preparing a medicament, health functional food, or prebiotic for preventing, improving or treating inflammatory bowel disease by improving intestinal permeability and tight junction integrity in an inflammatory intestinal environment.

Inventors

• Pi Zaihu

Assignees

• 株式会社爱恩枝

Dates

Publication Date

20260505

Application Date

20251029

Priority Date

20241030

Claims (19)

1. 1. A pharmaceutical composition for preventing or treating inflammatory bowel disease (inflammatory bowel disease, IBD) comprising a germinated oat extract and a pharmaceutically acceptable carrier.
2. 2. The pharmaceutical composition according to claim 1, wherein, The inflammatory bowel disease is one or more selected from the group consisting of ulcerative colitis (ulcerative colitis, UC), crohn's Disease (CD), irritable bowel syndrome, intestinal white plug disease (INTESTINAL BEHCET's disease), indeterminate colitis (INDETERMINATE COLITIS), infectious enteritis, bacterial enteritis, viral enteritis, amoeba enteritis, hemorrhagic rectal ulcers, ischemic bowel disease, radiation enteritis, tuberculosis enteritis, and intestinal leakage syndrome.
3. 3. The pharmaceutical composition according to claim 1, wherein, The germinated oats are obtained by germinating oat seeds at a 2:1 light-dark period for 1 to 3 days and treating with an inducer, and then treating at a 2:1 light-dark period for 2 to 5 days.
4. 4. The pharmaceutical composition according to claim 3, wherein, The inducer is abscisic acid, methyl jasmonate or a combination thereof.
5. 5. The pharmaceutical composition according to claim 1, wherein, The germinated oat extract is prepared by a method comprising the steps of: 1) Extracting germinated herba Avenae Fatuae with extraction solvent, and 2) Filtering the extract of step 1), concentrating or drying, Wherein the extraction solvent of the step 1) is one or more selected from the group consisting of water and an organic solvent, The drying in the step 2) is spray drying.
6. 6. The pharmaceutical composition according to claim 5, wherein, The organic solvent is one or more selected from the group consisting of alcohols having 1 to 5 carbon atoms, ethyl acetate, acetone, diethyl ether, chloroform, benzene, hexane, and methylene chloride.
7. 7. The pharmaceutical composition according to claim 1, wherein, The germinated oat extract improves intestinal permeability and tight junction (tight junction, TJ) integrity caused by inflammatory bowel disease.
8. 8. The pharmaceutical composition according to claim 1, wherein, The germinated oat extract promotes proliferation of intestinal beneficial bacteria.
9. 9. The pharmaceutical composition according to claim 8, wherein, The beneficial bacteria are one or more selected from the group consisting of lactobacillus plantarum (Lactobacillus plantarum) and lactobacillus delbrueckii (Lactobacillus delbrueckii).
10. 10. A health food composition for promoting intestinal health comprises germinated herba Avenae Fatuae extract.
11. 11. The health functional food composition according to claim 10, wherein, The germinated oat extract improves intestinal flora by promoting proliferation of intestinal beneficial bacteria.
12. 12. The health functional food composition according to claim 10, wherein, The germinated oat extract improves intestinal permeability and tight junction integrity caused by inflammatory bowel disease.
13. 13. The health functional food composition according to claim 10, wherein, The health functional food is in the form of one or more selected from the group consisting of tablet, capsule, pill, granule, liquid, powder, tablet, paste, syrup, gel, jelly, stick-shaped health functional food preparation, beverage, chewing gum and candy.
14. 14. A food composition for promoting intestinal health comprising germinated oat extract.
15. 15. The food composition of claim 14, wherein, The germinated oat extract improves intestinal flora by promoting proliferation of intestinal beneficial bacteria.
16. 16. The food composition of claim 14, wherein, The germinated oat extract improves intestinal permeability and tight junction integrity caused by inflammatory bowel disease.
17. 17. The food composition of claim 14, wherein, The food is one or more selected from the group consisting of various drinks, meats, sausages, breads, biscuits, rice cakes, chocolate, candies, snacks, cakes, pizzas, instant noodles, other pastas, chewing gums, ice cream and other dairy products, soups, beverages, alcoholic beverages and vitamin complex agents.
18. 18. A prebiotic composition for improving intestinal flora comprising germinated oat extract as an active ingredient.
19. 19. Use of germinated oat extract in preparation of medicine for preventing or treating inflammatory bowel disease, health food or food for promoting intestinal health, or prebiotics for improving intestinal flora.

Description

A composition containing germinated herba Avenae Fatuae extract for preventing or treating inflammatory bowel disease Technical Field The present invention relates to a composition for preventing or treating inflammatory bowel disease comprising a germinated oat extract, wherein the germinated oat extract has an increased content of avenanthramide. Background Inflammatory bowel disease refers to chronic inflammatory diseases caused by inflammation or ulceration of the intestinal tract of unknown origin, for example ulcerative colitis (ulcerative colitis, UC), crohn's Disease (CD), behcet's disease, and the like. Inflammatory bowel disease patients are very common worldwide, and recently have a significantly increasing trend in korea, but the cause and mechanism of the disease are complex, and are currently unknown. Current drugs for the treatment of inflammatory bowel disease include steroid immunosuppressants, 5-aminosalicylic acid (5-aminosalicylic acid; 5-ASA) which blocks prostaglandin (prostaglandins) production (e.g., sulfasalazine, etc.), mesalamine, etc. As described above, although anti-inflammatory and immunosuppressant drugs are prescribed, there are side effects such as nausea, vomiting, headache, hemolytic anemia, male infertility, etc., and a significant portion of patients do not respond to treatment or have reduced efficacy, so there is a continuing need to develop safer and more effective therapeutic drugs. Inflammatory bowel disease is characterized by an impairment of the integrity of the epithelial barrier caused by inflammation. Impaired barrier integrity and increased epithelial tight junction permeability may lead to reduced barrier function, which is known as "leakage gun". Recent studies have shown that the barrier is also very important in inflammatory bowel disease and a variety of diseases including autoimmune diseases associated with barrier integrity. Maintaining and enhancing barrier integrity is critical for the prevention and treatment of inflammatory bowel disease and other various diseases. In recent years, natural physiologically active substances having an anti-inflammatory effect have been known to be attracting attention as important potential therapeutic agents for the treatment of inflammatory bowel diseases. Oat (AVENA SATIVA l.) contains abundant bioactive components, and has various health promoting effects such as antioxidant, antidiabetic, antibacterial, anticancer, antihypertensive, immunoregulatory, antihyperlipidemic, antiobesity, heart protecting and antiinflammatory effects. According to the existing studies, germinated oats can regulate the expression of skin connective proteins, improve skin barrier function, and are effective in treating atopic dermatitis due to the damaged state of skin barrier. Oat comprises a plurality of phenolic components, wherein, the avenanthramide (AVENANTHRAMIDES, AVNs) is a phenolic alkaloid represented by the following chemical formula I, which is peculiar to oat, and the content of avenanthramide and phenolic compounds in germinated oat is far higher than that of un-germinated oat seeds. [ Formula I ] The known avenanthramide is a powerful antioxidant, has the effects of regulating blood pressure, inhibiting skin irritation, resisting arteriosclerosis and the like, and can be used for treating hearing loss, neurodegenerative diseases and the like recently. Accordingly, studies on the use of avenanthramide are actively underway and attracting attention as a useful ingredient useful for treating various diseases. However, in the context of inflammatory bowel disease (inflammatory bowel disease, IBD), the specific role of the active ingredient of germinated oats in combination with the intestinal permeability and the integrity of tight junctions (tight junction, TJ) has not been demonstrated. To this end, the inventors have used a comprehensive approach to define Inflammatory Bowel Disease (IBD) as a phenotype associated with interactions between the physiologically active compounds of germinated oats and genetic and proteomic environments that determine tight junction integrity, and have used a preliminary computer simulation (in silico) assessment using a Combination-oriented and term-uniform natural product database (conjugation-Oriented Natural Product Database with Unified Terminology, cocon) in conjunction with bioinformatic analysis and chemical profiling. Furthermore, the present inventors have verified efficacy assessment of computer simulation (in silico) predictions using a Caco-2 cell model as an in vitro (in vitro) model, based on which they have shown a basic mechanism of intestinal permeability of germinated oat extract (GERMINATED OAT EXTRACT, GOE) and confirmed that it is effective for inflammatory bowel disease due to its improved tight junction integrity in inflammatory intestinal environments, thereby completing the present invention. [ Prior Art literature ] [ Patent literature ] (Patent document 0001) Kore